Complex PCI

Resolute Onyx Drug-Eluting Stent

Alert Indications, Safety, and Warnings

Overview

Resolute Onyx™ DES offers flexibility, conformability, deliverability, and enhanced visibility† for complex percutaneous coronary intervention (PCI), including:   

Chronic total occlusion
Small vessels (2.0 mm)
Extra-large vessels (4.5­–5.0 mm)
Diabetic patients

Resolute Onyx Stent product image on white background

Chronic Total Occlusion

Resolute Onyx DES offers exceptional deliverability and enhanced visibility1 for complex chronic total occlusion (CTO) cases.

CTO PERFORMANCE BACKED BY EVIDENCE2‡

92.3% Procedural Success

96.2% Technical Success

1.1% TLR  at one year

0.6% Stent Thrombosis at one year

SEE MORE ABOUT CTO

Back to top

Small Vessels

When it comes to treating small vessels, Resolute Onyx DES offers the lowest crossing profile for superior deliverability3 and is engineered to expand from 2.0 mm to 3.25 mm.§

The Most Deliverable Stent3

Lower Is Better
Average Force (gF) 

Graph showing Resolute Onyx DES deliverability compared to others

ENGINEERED TO EXPAND

Graphic showing small maximum vessel expansions 2.0mm - 3.25 mm

Our smallest DES expands from 2.0–3.25 mm
and features low foreshortening when
expanded to 3.25 mm.†

3.25 mm
Post-dilatation limit for 2.0 mm sizes.

Back to top

Extra-Large Vessels

As the first DES with 4.5 and 5.0 mm sizes, Resolute Onyx DES expands treatment options for patients with extra-large vessels. It sustains structural strength and coating integrity when overexpanded and its 5 Fr compatibility is designed with the transradial approach in mind.  

Even Scaffolding at OverExpansion†§

Resolute Onyx DES
5.0 mm x 18 mm DES

Maximum distance between stent struts

1.62 mm maximum distance between stent struts

Synergy DES
4.0 mm x 20 mm DES

Image of Synergy DES scaffolding at over-expansion distance

1.87 mm maximum distance between stent struts

Deployed to 5.75 mm (maximum labeled overexpansion)§

SUSTAINED RADIAL STRENGTH†

Higher Is Better

Graph showing Resolute Onyx DES maintains higher compression resistance compared to others

Back to top

Diabetic Patients

In recent Medtronic studies, diabetes patients make up over 35% of the coronary stents implanted.4-5

The Medtronic DES portfolio was the first indicated for CAD treatment in patients with diabetes.2

Back to top

Onyx ONE Month DAPT Program

Evaluating Resolute Onyx DES in ~1,700 patients with 1-month DAPT

View the Data

EDUCATION

Explore the Transradial ARC Curriculum℠, designed to help you increase your procedural confidence.

See Training Programs

Resolute

Onyx DES

Resolute Onyx™ DES is designed to be placed inside a diseased coronary artery to keep the artery open so that blood can access the heart.

View Resolute Onyx DES

Resolute Onyx DES is not currently indicated for high bleeding risk patients on 1-month DAPT.

*

Medtronic and Medtronic logo are trademarks of Medtronic.  Third-party trademarks ("™*") belong to their respective owners.  All other brands are trademarks of a Medtronic entity.

†

Based on bench test data. May not be indicative of clinical performance.

‡

Endpoints from the Perspective Study (NCT02884206) were not powered.

§

The Resolute Onyx stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Post-dilatation required for overexpansion.

1

Compared to Resolute Integrity™ DES in benchtop testing. Data on file at Medtronic. May not be indicative of clinical performance.

2

Resolute Onyx DES, Instructions for Use.

3

Bench test data on file at Medtronic. May not be indicative of clinical performance. Testing performed on smallest diameters available for Abbott Xience Alpine™*, Biotronik Orsiro™*, Boston Scientific Promus Premier™*, Boston Scientific Synergy™*, Medtronic Resolute Integrity™, and Medtronic Resolute Onyx™ coronary stents.

4

Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. N Engl J Med. March 26, 2020;382(13):1208-1218.

5

Kirtane A, et al. One Month Dual Antiplatelet Therapy in High Bleeding Risk Patients: Primary Results of Onyx ONE Clear. Presented online at ACC 2020.